

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/206858 A1

(51) International Patent Classification:

A61K 31/501 (2006.01) A61P 35/00 (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2024/022279

(22) International Filing Date:

29 March 2024 (29.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/455,672	30 March 2023 (30.03.2023)	US
63/528,255	21 July 2023 (21.07.2023)	US

(71) Applicant: **REVOLUTION MEDICINES, INC.**
[US/US]; 700 Saginaw Drive, Redwood City, CA 94063
(US).

(72) Inventors: **KNOX, John, E.**; Revolution Medicines, Inc.,
700 Saginaw Drive, Redwood City, CA 94063 (US). **KOLTUN, Elena, S.**; Revolution Medicines, Inc., 700 Sag-
inaw Drive, Redwood City, CA 94063 (US). **SEAMON, Kyle**; Revolution Medicines, Inc., 700 Saginaw Drive, Red-
wood City, CA 94063 (US). **TOMLINSON, Aidan**; Revo-
lution Medicines, Inc., 700 Saginaw Drive, Redwood City,
CA 94063 (US). **WILDES, David, E.**; Revolution Medi-
cines, Inc., 700 Saginaw Drive, Redwood City, CA 94063
(US). **CREGG, James**; Revolution Medicines, Inc., 700
Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael, J.** et al.; Clark & Elbing
LLP, 101 Federal Street, 15th Floor, Boston, MA 02110
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: COMPOSITIONS FOR INDUCING RAS GTP HYDROLYSIS AND USES THEREOF

(57) Abstract: The present disclosure relates to therapies for treating cancer. In particular, the present disclosure relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a RAS(ON) GTP hydrolysis-promoting compound optionally in combination with an additional therapeutic agent (e.g., a RAS(OFF) inhibitor, RTK inhibitor, SHP2 inhibitor, or SOS1 inhibitor), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitor(s), kits comprising the compositions and methods of use therefor.



WO 2024/206858 A1